Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel prophylactic and/or therapeutic agent for neurogenic pain

A neuropathy, preventive agent technology, applied in the direction of nervous system diseases, non-central analgesics, anti-inflammatory agents, etc.

Inactive Publication Date: 2010-01-27
ASTELLAS PHARMA INC
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Regarding venlafaxine, milnacipran, duloxetine, and amitriptyline, etc., they are known to be effective in rat neuropathic pain models (Non-Patent Document 7 and Non-Patent Document 8), but there is no information about Reports of Phenyl Derivatives (including Indeloxazine) Effective in Neuropathic Pain

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel prophylactic and/or therapeutic agent for neurogenic pain
  • Novel prophylactic and/or therapeutic agent for neurogenic pain
  • Novel prophylactic and/or therapeutic agent for neurogenic pain

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0075] (experiment)

[0076] Using the L5 / L6 spinal nerve ligation model, according to the method of Kim et al., the analgesic effect on neuropathic pain was tested. That is, under phenobarbital anesthesia, the left L5 and L6 sciatic nerves of male SD rats were ligated with silk thread, and then evaluated. The evaluation method is studied based on the Von Frey Test of the plantar of the hind limbs of animals (Pain 1992, Vol. 50, p355-363). That is, using Von Frey Filament, weight is applied to the surgical side limb of the nerve ligation rat until the avoidance response is seen, and the minimum intensity (g) at which the avoidance response is seen is used as the pain threshold. Compound evaluation was performed 7 to 14 days from the day of surgery after stabilizing and seeing a decrease in the threshold. The von Fry test was performed on the day before the compound evaluation to perform grouping to reduce the variation in the average value of pain threshold. Solvent (Vehicle),...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an excellent prophylactic and / or therapeutic agent for neurogenic pain, which comprises a 2-¢(substituted-indene-7-yloxy)methyl!morpholine represented by the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. The prophylactic and / or therapeutic agent is particularly useful as a prophylactic and / or therapeutic agent for a pain associated with allodynia, algesthesia, hyperesthesia, spontaneous pain, cancer pain, trigeminal neuralgia, phantom limb pain, post-herpetic pain, fibromyalgia, low back / leg pain, thalamic pain, entrapment (compression) peripheral neuropathy, atypical facial pain or spinal cord injury, a pain associated with multiple sclerosis, a pain associated with chemotherapy-induced neuropathy, cancer pain against which a narcotic analgesic agent (e.g., morphine) acts unsatisfactorily, a pain associated with diabetic neuropathy, or the like.

Description

Technical field [0001] The present invention relates to a new drug use of a morpholine derivative or a pharmaceutically acceptable salt thereof as a preventive and / or therapeutic agent for neuropathic pain. Background technique [0002] Neuropathic pain is a type of intractable pain caused by abnormal functions of the peripheral or central nervous system. Examples of pathological conditions include pain associated with diabetic neurological disorders, post-herpetic pain, fibromyalgia syndrome, waist and lower limb pain, and thalamic pain. The pathogenesis is still unclear, but it is believed to be caused by abnormal continuous discharge of sensory nerves. Among the typical symptoms of neuropathic pain, in addition to spontaneous pain, there are allodynia, hyperalgesia, or hyperesthesia. These symptoms are manifested as pain expressed with characteristics such as "burning sensation", "pinting sensation" or "inductive touch". It has been known that the usual analgesics effective...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D265/30A61K31/5375A61P3/10A61P25/04
CPCA61K31/5375A61P25/00A61P25/02A61P25/04A61P29/00A61P3/10
Inventor 青木俊明田村诚司
Owner ASTELLAS PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com